ClinicalTrials.gg
Not yet recruitingNCT06370221Updated Apr 17, 2024

The Effect of Psoriatic Arthritis on Female Sexual Dysfunction

An observational study in Psoriatic Arthritis, sponsored by Egymedicalpedia. Not yet recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Egymedicalpedia · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
180
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Arthritis, Psoriatic with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Psoriatic · Egypt.

Started
2024
with 1 other
Observational
4 of 10
3 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Egymedicalpedia

Among the 10 studies in Arthritis, Psoriatic with a site in Egypt, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 3rd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

6 of the 10 studies in Arthritis, Psoriatic with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 20 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Psoriatic with a site in Egypt, or all of them as a file.
02

Study summary

Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.

Read the detailed description

Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.

Beside genetic factors, several environmental factors such as injuries, infections, stress, drugs, and immune defect take part in autoimmune pathogenesis of the disease. In addition, it has been reported that some hormones may also have a role in the pathogenesis of psoriasis, due to their effects on keratinocytes proliferation.

Studies revealed that sex hormones manifest a variety of biological and immunological effects in the skin which modulate the natural course of psoriasis.

Approximately 20-30% of patients with psoriasis may also have psoriatic arthritis, which often causes significant musculoskeletal pain that significantly impairs quality of life (QoL).

Although sexual dysfunction is a common complaint, affecting 30 to 70% of psoriasis patients, few studies have analyzed the impact of psoriasis and psoriatic arthritis on quality of sexual life.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The female sexual function index (FSFI) is a self-reported questionnaire that has been validated in Arabic, and is used to measure a woman's sexual function over the course of the past four weeks.

A reliable and accurate way to assess female sexual function is the FSFI. The six domains of sexual function-desire, arousal, lubrication, orgasm, satisfaction, and pain-are assessed by the 19 questions in this questionnaire. The response is scored between 0 and 5 on a 5-point Likert scale.

Disease Activity in Psoriatic Arthritis (DAPSA) Helps measure disease activity in psoriatic arthritis based on joint symptoms, CRP and pain evaluation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study will focuses on the relationship between the FSD and PsA;
  • The healthy controls will derive from a population within the same geographic area and ethnic background as PsA;
  • Used the same questionnaires/instruments of FSFI to diagnose FSD

Exclusion criteria

Exclusion Criteria:

  • pregnancy,
  • breastfeeding
  • being sexually inactive
  • having a partner with sexual dysfunction,
  • refusing to participate, or
  • being unable to read
  • Females with any sexual transmitted disease
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group A: Cases Group

    About 100 patient females suffering from Psoriatic arthritis and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients

    Behavioral: The effect of psoriatic Arthritis

  • Group B: Control Group

    About 80 healthy control females

    Behavioral: The effect of psoriatic Arthritis

Interventions

  • BehavioralThe effect of psoriatic Arthritis

    to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.

    Also known as: Female Sexual dysfunction

06

What researchers measure

Primary outcomes

  1. Evaluation of female sexual function

    To identify and understand the mechanisms of sexual problems in Psoriatic arthritis Patients in Qena university hospital.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Dec 2024, 6 months later.

Of 52 industry-sponsored observational studies under Arthritis, Psoriatic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 6 months is below that.

Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2024
First posted
Apr 17, 2024
StartEst.
Jun 1, 2024
Primary completionEst.
Dec 20, 2024
CompletionEst.
Dec 30, 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06370221
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Apr 17, 2024

Study contacts

Eisa Hegazy, Professor
Contact
eisa_mohamed4152@med.svu.edu.eg
+201094337795

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion